References
- Lloyd R V. Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 1983; 113: 198–206
- Annegers J F, Coulam C B, Abboud C F, Laws E R, Jr, Kurland L T. Pituitary adenoma in Olmsted County, Minnesota, 1935–1977. A report of an increasing incidence of diagnosis in women of childbearing age. Mayo Clin Proc 1978; 53: 641–643
- Sherman B M, Harris C E, Schlechte J, et al. Pathogenesis of prolactin-secreting pituitary adenomas. Lancet 1978; 2: 1019–1021
- Yen S S, Ehara Y, Siler T M. Augmentation of prolactin secretion by estrogen in hypogonadal women. J Clin Invest 1974; 53: 652–655
- Molitch M E. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985; 312: 1364–1370
- Gooren L J, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 1988; 66: 444–446
- Kovacs K, Stefaneanu L, Ezzat S, Smyth H S. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch Pathol Lab Med 1994; 118: 562–565
- Vedi S, Purdie D W, Ballard P, Bord S, Cooper A C, Compston J E. Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos Int 1999; 10: 52–58
- Vedi S, Bell K L, Loveridge N, Garrahan N, Purdie D W, Compston J E. The effects of hormone replacement therapy on cortical bone in postmenopausal women. A histomorphometric study. Bone 2003; 33: 330–334
- Wahab M, Ballard P, Purdie D W, Cooper A, Willson J C. The effect of long-term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy. Br J Obstet Gynaecol 1997; 104: 728–731
- Boivin G, Vedi S, Purdie D W, Compston J E, Meunier P J. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005; 36: 562–567
- Batrinos M L, Panitsa-Faflia C, Tsiganou E, Pitoulis G, Liapi C. Contribution to the problem of hyperprolactinaemia: experience with 4,199 prolactin assays and 117 prolactinomas. Int J Fertil Menopausal Stud 1994; 39: 120–127
- Asscheman H, Gooren L J, Assies J, Smits J P, de Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 1988; 28: 583–588
- van Kesteren P J, Asscheman H, Megens J A, Gooren L J. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337–342
- Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003; 59: 409–418
- Heaney A P, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest 2002; 109: 277–283
- Heaney A P. Pituitary tumour pathogenesis. Br Med Bull 2005; 75–76: 81–97
- Coombs N J, Taylor R, Wilcken N, Boyages J. Hormone replacement therapy and breast cancer: estimate of risk. BMJ 2005; 331: 347–349
- Anderson G L, Limacher M, Assaf A R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712